KRS 217.5406: Death of patient receiving experimental treatment absolves heirs of

liability for resulting debt.

If an eligible patient dies while being treated with an investigational drug, biological

product, or device, the patient's heirs are not liable for any outstanding debt related to the

treatment or to a lack of insurance as a result of the treatment.